Hamish joined SV in 2008 as a Venture Partner and is currently a Director at VHSquared. He has held a number of roles in SV portfolio companies; Hamish has been Interim CEO at X2-Pharma and Delenex Therapeutics as well as serving as Chief Commercial Officer at ESBATech.
Before joining SV, Hamish was CEO of Cambridge Antibody Technology (“CAT”). Prior to that, he held a series of senior R&D positions at AstraZeneca/Zeneca, including Head of the Cardiovascular Therapy Area and Senior Vice-President of Medical Research. Hamish started his industry career with Janssen, after working in clinical practice and cardiovascular research in the UK having been trained as a physician.
Outside of SV, Hamish is a Fellow of the Royal College of Physicians of Edinburgh, and a Fellow and past Board member of the Faculty of Pharmaceutical Medicine.
BSc (Hons), MBBS, Pharmacology, University of London